Search: onr:"swepub:oai:DiVA.org:uu-137255" >
Erythropoetin treat...
-
Birgegård, Gunnar,1944-Uppsala universitet,Institutionen för medicinska vetenskaper,Hematologi
(author)
Erythropoetin treatment can increase 2,3-diphosphoglycerate levels in red blood cells
- Article/chapterEnglish2001
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-137255
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-137255URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Some patients experience an improved well-being during treatment with recombinant human erythropoietin even with an unchanged Hb level. We have hypothesized that this may not be only a placebo effect. 2,3-diphosphoglycerate (2,3-DPG) in red blood cells increases in response to anaemia/hypoxia and causes a shift of the oxygen dissociation curve, allowing a more effective oxygen delivery. We have investigated red cell 2,3-DPG concentrations during erythropoietin treatment in healthy volunteers as a mediator of a possible physiological explanation. Thirteen healthy subjects with no iron deficiency were recruited and randomly assigned to a treatment group comprising five males and three females and a control group including three males and two females. The treatment group was treated with erythropoietin (Recormon), 20 IE/kg subcutaneously three times/week for 4 weeks. Blood samples were collected at each injection day and 10 days after the last injection and at corresponding times in the control group. B-Hb, red cell 2,3-DPG and P50 were measured by standard techniques and oxygen-releasing capacity was calculated. RESULTS: due to the sampling (26 ml each time, three times/week) the mean Hb level was lowered from 140.5 +/- 5.9 to 128.6 +/- 10.4 g/L in the control group whereas the erythropoietin treatment group maintained a mean Hb level of about 142 g/L (p<0.002). The 2,3-DPG mean level curve as well as that for oxygen releasing capacity also differed significantly between the two groups (p < 0.002), the treatment group showing higher levels. CONCLUSION: treatment with erythropoietin causes an increase in red cell 2,3-DPG levels.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Sandhagen, B.
(author)
-
Uppsala universitetInstitutionen för medicinska vetenskaper
(creator_code:org_t)
Related titles
-
In:Scandinavian Journal of Clinical and Laboratory Investigation61:5, s. 337-3400036-55131502-7686
Internet link
Find in a library
To the university's database